Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

TAFLUPROST 0.0015% EYE DROP

Tafluprost
$2.8176per EA

Strength

.0045 mg/.3mL

Manufacturer

Sandoz Inc.

NDC

00781618487

Classification

Generic

Dosage Form

SOLUTION/ DROPS

Route

OPHTHALMIC

Last Updated

4/22/2026

Active Ingredients

TAFLUPROST

Approval Type

Generic (ANDA)

FDA Application

ANDA209040

On Market Since

12/5/2022

Pharmacological Classes

Increased Prostaglandin Activity
Prostaglandin Analog
Prostaglandin Receptor Agonists
Prostaglandins

Price History

1W

0.0%

1M

-4.8%

3M

-7.0%

6M

-1.5%

1Y

-21.5%

3Y

-32.0%

5Y

N/A

All

-34.4%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

TAFLUPROST 0.0015% EYE DROP
Generic
42571026473•Micro Labs Limited
$2.8176
per EA
TAFLUPROST 0.0015% EYE DROP
Generic
66993042930•Prasco Laboratories
$2.8176
per EA
BIMATOPROST 0.03% EYE DROPS
Generic
42571012835•Micro Labs Limited
$7.7920
per ML
BIMATOPROST 0.03% EYE DROPS
Generic
60505058304•Apotex Corp.
$7.7920
per ML
BIMATOPROST 0.03% EYE DROPS
Generic
62332050725•Alembic Pharmaceuticals Inc.
$7.7920
per ML
BIMATOPROST 0.03% EYE DROPS
Generic
65862080244•Aurobindo Pharma Limited
$7.7920
per ML
BIMATOPROST 0.03% EYE DROPS
Generic
70069040101•Somerset Therapeutics, LLC
$7.7920
per ML
BIMATOPROST 0.03% EYE DROPS
Generic
72266013901•Fosun Pharma USA Inc.
$7.7920
per ML
BIMATOPROST 0.03% EYE DROPS
Generic
42571012821•Micro Labs Limited
$7.8274
per ML
BIMATOPROST 0.03% EYE DROPS
Generic
60505058301•Apotex Corp.
$7.8274
per ML

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy